A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped High SF rate (less treatment-naïve subjects \& subjects with viral load \<100000). Reevaluation in scientific position in India after internal discussion.

Conditions

Human Immunodeficiency Virus Infections

Interventions

DRUG: Rilpivirine 25 mg
DRUG: Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)

Sponsor

Janssen Research & Development, LLC